Powered by

Bringing Brigatinib to Neurofibromatosis Type-2 Patients: From Promising Potential to Platform Clinical Trial; Children's Tumor Foundation and Takeda Pharmaceuticals Launch INTUITT for NF2 in Partnership with 6 Leading Medical Centers

May 29, 2020 - PR Newswire

PR Newswire

NEW YORK, May 29, 2020 /PRNewswire-PRWeb/ -- The Children's Tumor Foundation (CTF) announced today a significant advancement in care for neurofibromatosis type 2 patients with the launch of a new clinical trial called INTUITT-NF2, an innovative platform trial which will evaluate multiple treatments simultaneously. This initiative is a result of the landmark work of CTF's visionary Synodos for NF2 research collaborative, its NF2 Accelerator Initiative, an investment from Takeda ...